BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Celebrex celecoxib: Phase II/III data

A double-blind, U.S. Phase II/III trial in 240 patients at high risk for developing non-melanoma skin cancers showed that twice-daily 200 mg oral Celebrex for 9 months missed the primary endpoint of significantly reducing the incidence of new actinic keratoses at 9 months vs. placebo as measured by the ratio of new lesions per patient...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >